Nuance announces another acquisition

Nuance Communications has acquired J.A. Thomas and Associates (JATA), a developer of physician-oriented, clinical documentation improvement (CDI) programs for the healthcare industry.

JATA has provided technology and professional services that improve clinical documentation for healthcare providers for more than two decades. Its managed CDI technology has helped more than 500 hospitals improve patient care documentation by starting the CDI process with the physician at the point of care.

With JATA integrated into a single platform for end-to-end clinical documentation, the combined Nuance Healthcare solution should help hospital efficiently transition to ICD-10, the company said in a release. Nuance will deliver documentation by integrating the CDI strategies from JATA into Nuance’s Clinical Language Understanding (CLU) technology. Nuance CLU, enhanced with JATA CDI strategies, will power both Dragon Medical 360 physician technologies and Quantim HIM computer-assisted coding and CDI technologies.

Nuance anticipates market growth as only 600 hospitals currently use a CDI and coding technology, with that number expected to increase to 2,400 hospitals by 2015.

Nuance announced its intention to purchase QuadraMed's Quantim HIM business last week.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

CMS finalized a significant policy change when it increased the Medicare payments hospitals receive for performing CCTA exams. What, exactly, does the update mean for cardiologists, billing specialists and other hospital employees?

Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.